Given the non-selective nature of Kv1.3 blockers such as PAP-1, development of Kv1.3 blockers with higher selectivity is essential for realising the therapeutic potential of Kv1.3 blockade in AD. The gene discussed is KCNA3; the disease is Alzheimer disease.